Search
Moxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approvedDue to these modifications, moxidectin is classified as a second generation macrocyclic lactone.
Pork collagen
go.drugbank.com/drugs/DB14100ApprovedIt serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods. … It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden.
Alfuzosin
go.drugbank.com/drugs/DB00346ApprovedThe prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division. … [A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma
Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. ...
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigational[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).
Histamine
go.drugbank.com/drugs/DB05381ApprovedInvestigationalA depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor
Ezogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnIt is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.